Everest Clinical Research, an Arlington Capital Partners Portfolio Company, Announces the Acquisition of Brightech International

WASHINGTON–(BUSINESS WIRE)–Everest Clinical Research (“Everest”), a leading full-service contract research organization (“CRO”) with deep expertise in biostatistics and statistical programming, today announced it has acquired Brightech International (“Brightech” or the “Company”).

Founded in 2002, Brightech is a leading CRO that specializes in complex, value-add biostatistics, programming, and clinical data management services. Similar to Everest, Brightech has earned a highly-regarded reputation as a critical partner for some of the world’s largest pharmaceutical and biotech companies. In addition to its New Jersey headquarters, Brightech has an expanded global reach with a second office in Asia. Brightech will continue to be led by Dr. Tai Xie, the Company’s CEO and founder, and the existing management team.

Malcolm Little, a Partner at Arlington Capital Partners, said, “The highly complementary Brightech acquisition is a great start towards accelerating Everest’s inorganic growth. Together, the combined businesses will be better suited to pursue investment opportunities that strengthen existing centers of excellence, add new services, and increase geographic reach. We look forward to supporting Everest’s continued growth through further investments in people, processes, and additional acquisitions.”

Commenting on the announcement, Everest CEO Irene Zhang said, “We are extremely excited to partner with Dr. Xie and his entire team as we continue to expand Everest’s world-class capabilities. Brightech brings with it a highly educated, experienced, and dedicated workforce, including numerous PhDs and Master’s degree holders. With our combined deep bench of biostatical and clinical data management capabilities, Everest’s broader full-service clinical trial services, and now over 500 employees globally, we will be even better positioned to solve our clients’ most challenging problems.”

Dr. Xie, CEO of Brightech, added, “There is an incredibly strong fit between our two organizations. We both have deeply engrained cultures of innovation, dedication to our customers, and high quality services. We look forward to working together with the Everest team.” He added, “Everest’s scale, resources, and infrastructure will allow us to broaden the scope of our services to existing and future customers while also providing our employees with even more opportunities.”

Bilal Noor, a Principal at Arlington Capital Partners, added, “This investment further expands and diversifies Everest’s blue-chip customer base while also deepening the platform’s core capabilities in fast-growing therapeutic areas such as Oncology, Central Nervous System, and Immunology. We are thrilled to welcome the entire Brightech team into the Everest family and look forward to our successful partnership together.”

About Everest Clinical Research Corporation

Everest is a full-service contract research organization (“CRO”) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. Everest serves some of the best-known companies and works with many of the most advanced drugs, biologics, and medical devices in development today. Founded in 2004, Everest has a strong foundation as a statistical and data management center of excellence. Building on this foundation, Everest has successfully developed and established itself as a full-service CRO. Operating primarily in North America, with headquarters located in Toronto, Ontario, Canada, a second office in Little Falls, New Jersey, USA and a third office in Shanghai, China, Everest is known in the industry for its high quality deliverables, superior customer service, and flexibility in meeting clients’ needs.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, DC-based private equity firm that has managed approximately $7 billion in capital commitments. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field.

For more information: www.arlingtoncap.com

Contacts

Malcolm Little & Bilal Noor

(202) 337-7500